CERS — Cerus Corporation
$1.99
+$0.04 (+2.32%)
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety.
Market Cap
$400.88M
Forward P/E
132.3x
52-Week Range
N/A
CERS Price History
Revenue vs. Net Income
$206M
Revenue · FY2025
Annual. Net margin is shown under each year.
Free Cash Flow
$1.1M
FCF · FY2025
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
-5.7%
ROCE · FY2025
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
1.4x
Assets ÷ liabilities · FY2025
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
1.8%
CapEx · FY2025
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
+3.3%
Dilution · FY2025
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
